Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s worst performing stocks. Wall Street’s main indices bounced back on Friday, ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...

Aadi Bioscience, Inc.  ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Beasley Broadcast Group, Inc. ("Beasley" or the "Company"), a multi-platform media company, announced today that it will report its 2024 full-year financial results before the market opens on Thursday ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...